government
Government Price negotiations on Ozempic and Wegovy
The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
Latest
category:side-effects
Pancreatitis and Gallstones after massive weight loss
We look into pancreatitis and gallstones issues that caused one death and more hospitalizations, caused at least in part by GLP1s
category:howto
What's the best injection site for GLP1s?
What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.
category:benefits
Zepbound coverage for Sleep Apnea gets Agency approval
Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.
category:news
Robert F. Kennedy Jr vs GLP1
RFK Jr.'s appointment and it's effect on GLP1s. Is it truly anti-GLP1? Or a case of tactics?
research
Research suggesting GLP1 is a brain drug
Why has modern scientific opinion shifted to GLP1 being a brain drug rather than a gut drug? We dive into the critical research paper supporting the shift.
usecase:kidney-disease
Tirzepatide's benefits extend to Kidney Disease
Tirzepatide (Mounjaro, Zepbound) shows results in weight loss and Hba1c reduction for southerners, critical to kidney disease treatment.
company:hikma
Another Generic Liraglutide launch: Hikma Phamaceuticals
A new player enters the generic GLP1 market - Hikma Pharmaceuticals. As the second generic Liraglutide provider, accessibility of GLP1s has never been better.
category:news
HIMS to offer Liraglutide after shortage rule changes
HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?
chemical:lixisenatide
Adlyxin's 2025 Patent expiry
Aldyxin' approaching 2025 patent expiry and what it could mean for new GLP1 drugs.
categeory:watercooler
Research models applied to GLP1s and Plateaus
New research that shows a benefit to appetite feedback control circuits via mathematical modeling, showing the benefits of using GLP1s.
22.7% weight loss yet Novo Nordisk stock drops 27%
Novo Nordisk's new CagriSema drug showed weight loss results that are *stunning*, but less than what Wall Street expected.